Recent Company News

• 05:38 AM ET Apr 15, 2026
  

  CSPC Pharmaceutical Group obtains clinical trial approval for SYS6051 for advanced solid tumors (HK$9.44, 0.00)

• 09:35 PM ET Apr 07, 2026
  

  StreetAccount Sector Summary - China Healthcare March Recap

• 08:03 AM ET Apr 07, 2026
  

  Corbus Pharmaceuticals announces broad alignment with FDA on registration path for CRB-701 in 2L HNSCC and cervical cancer; CMO to step down ($10.14, 0.00)

• 05:08 AM ET Apr 02, 2026
  

  Immunovant announces Phase 3 study results for batoclimab in Thyroid Eye Disease (TED) ($25.10, 0.00)

• 07:09 AM ET Mar 31, 2026
  

  Phase III clinical trial of Anbenitamab Injection (KN026) combined with Docetaxel for Injection (Albumin-bound) (HB1801) meets primary endpoint

• 11:21 PM ET Mar 26, 2026
  

  StreetAccount Summary - Asia Sector Highlights

• 11:08 PM ET Mar 26, 2026
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 12:31 AM ET Mar 25, 2026
  

  StreetAccount Metrics Recap - CSPC Pharmaceutical Group FY Earnings (HK$8.41, +0.08)

• 12:26 AM ET Mar 25, 2026
  

  CSPC Pharmaceutical Group reports FY net income attributable CNY3.88B vs FactSet CNY4.99B [25 est, CNY3.45-6.38B] (HK$8.41, +0.08)

• 08:05 PM ET Mar 23, 2026
  

  Alphamab Oncology doses first patient in phase III clinical study of KN026 for adjuvant treatment of HER2+ BC (HK$8.04, 0.00)